Contract: $650,000 - National Institutes of Health - Aug. 6, 2009
No votes have been cast for this award yet
Award Description: The objectives of these contracts are to conduct Phase 2 and early clinical trials of NCI-sponsored agents, to evaluate biologic effects of these agents on their molecular targets, to evealuate other relevant biologic effects and to determine clinically relevant outcomes/correlates. Major emphasis shall be on Phase 2 studies, pilot protocols that explore promising combination therapies, and high priority studies that are pivotal for drug development and require rapid initiation, completion and data reporting. The NCI-IND agents to be studied shall include the following: a) Agents developed by the pharmaceutical industry and provided to the NCI for collaborative development; and agents developed by academic investigators and/or the Developmental Therapeutics Program (DTP), DCTD, NCI: b) Agents which have completed some or all Phase 1 testing, and; c) Combinations of agents for which the individual toxicities are known.
Project Description: AS DEFINED IN THE AWARD DESCRIPTION.
Jobs Summary: No jobs were created for the period ending September 30, 2009. (Total jobs reported: 0)
Project Status: Not Started
This award's data was last updated on Aug. 6, 2009. Help expand these official descriptions using the wiki below.